🇺🇸 FDA
Pipeline program

Granexin® gel (200 μM)

2019-BURN-01

Phase 2 small_molecule terminated

Quick answer

Granexin® gel (200 μM) for Second Degree Burn is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Second Degree Burn
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials